skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Whilst many market observers predicted a reduction in investor appetites for life science initial public offerings at the end of 2015, investors continued to support life sciences IPOs globally in 2016. What really set 2016 apart from previous years was both the global diversity of the offerings – the US was no longer as dominant as it once was for biotech IPOs – and the fact that the top three offerings accounted for more than two thirds of the total sums raised.

Download Your Report Today And Discover

 

• Monthly Healthcare and Biotech Fund Flows Versus Performance Since 2014

• Daily Healthcare and Biotech Fund Flows (July 1, 2016 – October 16, 2016)

• Top 10 Fundraisers Get Mix Of Venture, Corporate Support

• Strategic Investing Versus Investing For A Portfolio

• And much more

 

Find out more about how pharma, biotech and medtech can raise capital in 2017. Download your complimentary report from Pharma Intelligence Informa and EBD Group today

BST

Read also

  • Biomedtracker: see the drug development process through anal...

    39th Annual J.P. Morgan Healthcare Conference 2021

    Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Gene therapy manufacturers

    Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

  • Biomedtracker: see the drug development process through anal...

    Deconstructing the KRAS+ market opportunity

    By Daniel Chancellor

    With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

    Topics BioPharmaceutical Drug Review

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: